CV Therapeutics Announces Abstract to Be Presented at Heart Rhythm 2006 Scientific Sessions
Friday May 5, 7:00 am ET
PALO ALTO, Calif., May 5 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX - News) today announced that an abstract on a preclinical study has been accepted for presentation at the Heart Rhythm 2006 Scientific Sessions, taking place in Boston, MA from May 17-20, 2006.
ADVERTISEMENT
Ranolazine Suppresses Atrial Fibrillation by Exerting a Marked Use-dependent Block of Sodium Channel Current in Canine Atrium but not Ventricle. Saturday, May 20, 2006 from 9:30 a.m. to 10:30 a.m. Eastern Time, Exhibit Hall, Boston Convention and Exhibition Center. Poster Session #P6-9.
Additional information regarding the Heart Rhythm 2006 Scientific Sessions can be accessed at heartrhythm2006.org .
About CV Therapeutics
CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON® (perindopril erbumine) Tablets. Ranexa is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. In addition, CV Therapeutics co-promotes ACEON®, an ACE inhibitor, for reduction of the risk of cardiovascular mortality or nonfatal myocardial infarction in patients with stable coronary artery disease and treatment of essential hypertension.
CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Regadenoson has not been approved for marketing by any regulatory authorities. |
